Background Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in
hematological patients; both were evaluated prospectively in 42 patients with multiple …

Multiple myeloma (MM) patients are at excess risk for clinically significant COVID19
infection. BNT162b2 mRNA COVID19 (BNT162b2) vaccine provides effective protection …

Background Haematological malignancies and their treatments are likely to affect SARS-
CoV-2 vaccine efficacy. We aimed to evaluate serological response to BNT162b2 vaccine in …

Evidence regarding the effectiveness of COVID-19 vaccine in patients with impaired
immunity is limited. Initial observations suggest a lower humoral response in these patients …

The mRNA vaccines BNT162b2 and mRNA-1273 have robust safety and efficacy against
COVID-19 among immunocompetent individuals (Creech et al., 2021). However, many …

Patients with multiple myeloma frequently present with substantial immune impairment and
an increased risk for infections and infection-related mortality. The risk for infection with …

The rapid development of safe and effective vaccines is imperative to attenuate the impact of
the COVID-19 pandemic. 1 Patients with multiple myeloma (MM) are at increased risk of …

During the SARS-CoV-2 pandemic, patients with multiple myeloma (MM) are at increased
risk of developing severe COVID-19 and succumbing to the disease (Chari et al., 2020) …

Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients
with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were …

Despite the efficacy of COVID-19 vaccines in healthy individuals, multiple myeloma (MM)
patients are immunocompromised and mount suboptimal humoral and cellular responses …